| [1] |
Ren Lu, Xie Xiaoli, Zhang Kun, Wang Lijuan.
Effects and mechanisms of dihydroartemisinin combined with carfilzomib on the activity， proliferation， and apoptosis of multiple myeloma cells
[J]. Journal of International Oncology, 2024, 51(3): 129-136.
|
| [2] |
Zhang Yuxiao, Zhang Liansheng, Li Lijuan.
Research status and application prospect of a novel immune checkpoint TIGIT in the immunotherapy of multiple myeloma
[J]. Journal of International Oncology, 2023, 50(2): 122-125.
|
| [3] |
Zhao Jianhao, Duan Yanchao.
Research progress in the pathogenesis of extramedullary disease in multiple myeloma
[J]. Journal of International Oncology, 2023, 50(1): 55-59.
|
| [4] |
Gao Shan, Lu Minqiu, Shi Lei, Chu Bin, Fang Lijuan, Xiang Qiuqing, Wang Yutong, Ding Yuehua, Bao Li.
Clinical efficacy and safety of ixazomib-based therapy in the treatment of relapsed or refractory multiple myeloma
[J]. Journal of International Oncology, 2022, 49(5): 286-291.
|
| [5] |
Sun Ruijie, Shan Ningning.
Immune, targeted therapy and related issues of relapsed/refractory multiple myeloma
[J]. Journal of International Oncology, 2021, 48(6): 381-384.
|
| [6] |
Hou Yuanmei, Li Junpeng.
Recent advances in immunotherapy for relapsed or refractory multiple myeloma
[J]. Journal of International Oncology, 2020, 47(12): 765-768.
|
| [7] |
Yao Yixuan, Wang Huan, Xia Jun, Wang Jing, Sun Chao, Sun Hongli, Zhou Xin.
Correlations between peripheral absolute lymphocyte count and clinicopathological characteristics of the elderly patients with multiple myeloma and its prognosis
[J]. Journal of International Oncology, 2018, 45(6): 347-351.
|
| [8] |
Liu Xiaolan, Guan Tao, Su Liping.
Detection and clinical application of minimal residual disease in multiple myeloma
[J]. Journal of International Oncology, 2018, 45(1): 56-.
|
| [9] |
Yuan Qing, Chen Shaoshui.
Application of circulating microRNAs in multiple myeloma
[J]. Journal of International Oncology, 2018, 45(1): 53-.
|
| [10] |
Qiao Yinbiao, Yang Bo.
Research progress of HGF/c-MET signaling pathway inhibitors in antipancreatic cancer
[J]. Journal of International Oncology, 2017, 44(4): 304-306.
|
| [11] |
NIE Lin, XU Yu-Qing.
Relationship between abnormal activation of HGF/cMet signaling pathway and EGFRTKI acquired resistance in nonsmall cell lung cancer
[J]. Journal of International Oncology, 2016, 43(8): 703-705.
|
| [12] |
WANG Wei-Yuan, GUO Dong-Mei, HAN Tian-Jie, TENG Qing-Liang.
Role and treatment strategy of hypoxia in the pathogenesis of multiple myeloma
[J]. Journal of International Oncology, 2016, 43(7): 552-554.
|
| [13] |
LI Chun-Pu, WANG Jing, LIU Yan, WANG Ling, LI Ban-Ban, ZHANG Kai-Gang, GUO Dong-Mei.
Inhibition of RPMI8226 myeloma cell xenografted tumor angiogenesis by downregulation of Notch1
[J]. Journal of International Oncology, 2015, 42(8): 661-.
|
| [14] |
Wang Yingying, Zhu Qi.
cAMP signaling pathway and multiple myeloma
[J]. Journal of International Oncology, 2014, 41(5): 368-370.
|
| [15] |
LI Ban-Ban, GUO Dong-Mei, TENG Qing-Liang.
Roles of hypoxia and Notch1 in multiple myeloma
[J]. Journal of International Oncology, 2013, 40(7): 542-546.
|
